AOD-9604 and fragment 176–191: mechanisms and risks

The main promise of AOD-9604 and fragment 176-191 sounds like a pharmacologist's dream: take from growth hormone only the ability to break down fat and get rid of everything else - the effect on growth, sugar, swelling. The editors analyze what is known about the mechanism of action of these peptides, how much their "selectivity" is confirmed, and what side effects and risks are described in the literature.

The two faces of growth hormone

Growth hormone acts on adipose tissue in two ways. On the one hand, it stimulates lipolysis — the breakdown of triglycerides into fatty acids and glycerol — and inhibits fat accumulation. On the other hand, released fatty acids and direct intracellular effects of GH reduce the sensitivity of muscles and liver to insulin.

That is why the risk of hyperglycemia and diabetes increases in patients who receive somatropin, and especially in people with acromegaly. In addition, the GH receptor triggers the synthesis of IGF-1, which is associated with growth and proliferative effects, as well as sodium and water retention, which is manifested by edema.

Monash researchers hypothesized that the lipolytic action is partially encoded in the C-terminal region of the GH molecule and can be reproduced by a short peptide without binding to the classical growth hormone receptor. If so, such a peptide should burn fat without causing insulin resistance or increasing IGF-1.

This hypothesis became the basis for AOD9604 and for the sale of "fragment 176-191". To evaluate it, you need to separate the experimental facts from the assumptions made by the market.

Hypotheses of the mechanism of action of the fragment

In animal studies, AOD9604 reduced weight gain and fat stores in obese mice and increased fat oxidation (Ng et al., 2000). The authors reported that the peptide stimulated lipolysis and inhibited lipogenesis in adipose tissue, while it did not bind to the GH receptor in the same way as the full hormone.

Heffernan et al. (2001) compared the effects of full-length GH and AOD9604 in obese and β3-adrenoceptor knockout mice. The obtained data indicated the possible participation of β3-adrenergic mechanisms in the lipolytic action, and in animals with a normal receptor, an increase in its expression in adipose tissue was observed.

The exact molecular target of the fragment has not yet been established. There is no universally recognized “AOD9604 receptor” and most of the mechanistic data have been obtained in rodents. They should be transferred to humans with caution: the regulation of lipolysis, the role of β3-receptors, and metabolism in mice and humans are markedly different.

Importantly, in human studies of AOD9604, the lipolytic effect did not translate into a clinically significant reduction in body weight. Possible explanations are insufficient bioavailability, differences between species, compensatory mechanisms of the body. None of them have been fully tested.

How does the mechanism differ from the full GH

The most consistently reproducible result is that AOD9604 does not have the effects characteristic of full growth hormone. In animal models and clinical studies, the peptide did not increase the level of IGF-1 and did not worsen indicators of carbohydrate metabolism. This is consistent with the fact that it does not activate the GH receptor and the JAK2–STAT5 signaling pathway.

Accordingly, typical effects of somatropin are not expected for the fragment: bone and soft tissue growth, carpal tunnel syndrome, severe fluid retention. It is this "purity" that sellers use as the main argument, forgetting to add that most of the proven effects of GH disappear along with the side effects.

AOD-9604 and the natural hGH fragment 176–191 are closely related, but are not chemically identical: AOD-9604 begins with tyrosine, whereas the natural fragment begins with phenylalanine. Mechanistic similarity must not be treated as proof of identical effects. The available studies need to be matched to the molecule actually tested.

AOD9604 has been tested in humans. Comparable safety evidence is not established for an unspecified product labeled “fragment 176–191”; neither its name nor structural similarity demonstrates that those findings apply.

Side Effects: What Research Has Shown

A pooled analysis of clinical studies of AOD9604 (Stier et al., 2013) showed that the incidence of adverse events in the peptide groups was similar to placebo. There were no changes in IGF-1, deterioration of glucose tolerance, and the formation of antibodies to the peptide, which is an important indicator for protein preparations.

These results relate to controlled conditions: certified substance, defined doses, limited duration and selection of participants. They do not describe a situation where a person self-administers a product of unknown origin for months or combines it with other substances.

• Described in studies: tolerability similar to placebo; moderate reactions, typical for any studies, without a specific profile.
• Theoretical, not confirmed: effect on lipid profile, interaction with β-adrenergic system.
• Unknown: effects of long-term use, effects of high doses, safety during pregnancy.

Separate human safety evidence for the natural fragment is very limited. Extrapolating from AOD9604 remains uncertain and cannot establish safety merely by confirming a product’s identity or purity.

Risks that sellers do not write about

Risks include both incompletely understood pharmacology and the circumstances of use. Unapproved products are often sold for subcutaneous injection. Loss of sterility can cause infections or abscesses, and reused equipment can transmit infections; none of this is a reason to attempt self-injection.

Unknown composition is the second problem. Products "for research" may contain other peptides, in particular, complete analogs of growth hormone, bacterial endotoxins, solvent residues. The side effects that one associates with a "fragment" may actually be caused by impurities.

The third risk is psychological and metabolic. Belief in a "fat-burning injection" distracts from methods with proven effectiveness, and for athletes — creates a threat of disqualification, because GH fragments are directly mentioned in class S2 of the WADA List.

People with obesity, diabetes, or metabolic syndrome should discuss registered treatments with proven efficacy and a clear safety profile with their doctor.

Editorial conclusions

Studies of AOD9604 did not show the same IGF-1 and glucose effects as full growth hormone, while its proposed lipolytic benefits are supported mainly by animal data. These findings cannot automatically be transferred to every product called fragment 176–191.

Some controlled AOD9604 studies reported tolerability similar to placebo, but the larger weight-loss study did not establish efficacy. “Safe but ineffective” is too strong: the available trials do not establish long-term or unsupervised safety.

Product identity, contamination, injection risks and anti-doping consequences add to the unresolved pharmacological safety questions.

We also recommend that you read our articles on the general difference between AOD-9604 and fragment 176-191, the side effects of somatropin, and how to recognize substandard peptide products.

References

1. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278.
2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189.
3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1–2):7–15.
4. Holt RIG, Ho KKY. The use and abuse of growth hormone in sports. Endocr Rev. 2019;40(4):1163–1185.
5. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609.
6. World Anti-Doping Agency. Prohibited List. Montreal: WADA; поточна редакція.